Pre- and post-operative antiviral and anti-inflammatory treatment with IFN has been shown to reduce early and late tumor recurrence rates in HCC patients with HBV or/and HCV infection [11, 12]. The gene discussed is IFNA1; the disease is hepatocellular carcinoma.